PRGO Stock Recent News

While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Perrigo (PRGO) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.86 per share a year ago.

Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN , Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic growth of 0.7% was more than offset by unfavorable impacts from divested businesses and exited product lines and currency translation of 2.3%. Organic2 net sales increased 0.7%, as higher net sales in the Nutrition, Skin Care and Women's Health Categories more than offset previously disclosed lost distribution of lower margin products in U.S. Store Brand of 1.2%, and lower net sales in the Pain and Sleep-Aids and

DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS 2025 Global Consumer and Retail Conference, on Wednesday, March 12 at 10 AM ET in New York City.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.

Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.

DUBLIN , Feb. 19, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend.

--WNBA and Opill® continue partnership with Level The Court initiative-- GRAND RAPIDS, Mich. , Feb. 4, 2025 /PRNewswire/ -- Today, Opill®— the first and only daily birth control pill available without a prescription in the U.S. —launched an educational college campus tour and the next phase of its multiyear partnership with the Women's National Basketball Association (WNBA) with a goal of expanding reproductive health education and access to birth control resources.

DUBLIN, Ireland , Jan. 31, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2024 financial results after the U.S. equity markets close on February 27, 2025. The Company plans to host its Virtual Investor Day on February 28, 2025, beginning at 8:00 AM EST.